Hantz Financial Services Inc. Raises Stock Holdings in Sanofi $SNY

Hantz Financial Services Inc. lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 16.3% in the second quarter, HoldingsChannel.com reports. The fund owned 56,504 shares of the company’s stock after acquiring an additional 7,923 shares during the period. Hantz Financial Services Inc.’s holdings in Sanofi were worth $2,730,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of SNY. Brighton Jones LLC increased its position in shares of Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Sanofi by 124.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company’s stock valued at $1,344,000 after acquiring an additional 13,358 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Sanofi by 15.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 133,604 shares of the company’s stock valued at $7,260,000 after acquiring an additional 18,274 shares during the last quarter. Private Trust Co. NA increased its position in shares of Sanofi by 19.8% during the first quarter. Private Trust Co. NA now owns 4,220 shares of the company’s stock valued at $234,000 after acquiring an additional 697 shares during the last quarter. Finally, Checchi Capital Advisers LLC increased its position in Sanofi by 9.9% in the first quarter. Checchi Capital Advisers LLC now owns 13,080 shares of the company’s stock worth $725,000 after buying an additional 1,180 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

Sanofi stock opened at $50.58 on Friday. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The business has a 50-day simple moving average of $48.69 and a 200 day simple moving average of $49.55. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. The stock has a market cap of $124.20 billion, a price-to-earnings ratio of 11.85, a PEG ratio of 1.38 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 24th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.60 by $0.10. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business had revenue of $14.53 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same period in the previous year, the business earned $2.25 earnings per share. The firm’s revenue was down 7.5% on a year-over-year basis. On average, research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of recent research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, October 8th. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Finally, Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $56.00 to $58.00 in a report on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.